Summary

The global Antibody-drug Conjugates market size is predicted to grow from US$ 15143 million in 2025 to US$ 39442 million in 2032; it is expected to grow at a CAGR of 14.7% from 2026 to 2032.
Antibody-drug Conjugates are targeted biopharmaceuticals that combine a monoclonal antibody with a cytotoxic or biologically active payload through a chemical linker. The antibody recognizes a tumor-associated antigen, enabling selective internalization or localized payload release while reducing systemic exposure relative to conventional chemotherapy. Core product attributes include antigen specificity, antibody format, linker stability and cleavage mechanism, payload class and potency, drug-to-antibody ratio, conjugation-site distribution, aggregation level, formulation stability and dosing strength. Commercial products are primarily supplied as intravenous liquid or lyophilized injections for solid tumors and hematologic malignancies. This study focuses on commercial Antibody-drug Conjugates and evaluates the market by payload mechanism, linker type, conjugation technology, target antigen, therapeutic indication and geographic market. Market value is measured primarily through manufacturer-recognized net product sales because vial strengths, body-weight-based dosing, treatment cycles, regional reimbursement and alliance accounting differ materially between products.
Key Findings
Global Antibody-drug Conjugate shipments reached approximately 6.0 million standard vial equivalents in 2025
The weighted average manufacturer selling price was approximately USD 2,580 per standard vial equivalent in 2025
More than 15 Antibody-drug Conjugates had entered commercial use across major markets by 2025
North America remains the largest regional market supported by rapid launch uptake and premium oncology reimbursement
Solid tumors have become the principal demand base while hematologic malignancies retain established clinical positions
Topoisomerase I inhibitor payloads and cleavable linkers are driving the fastest product expansion
Market Trends
Antibody-drug Conjugates are evolving from relatively heterogeneous first-generation products toward more stable, homogeneous and therapeutically differentiated platforms. Development priorities are shifting from late-line hematologic indications to larger solid-tumor populations, earlier treatment lines and biomarker-defined pan-tumor opportunities. New products increasingly use highly potent topoisomerase I inhibitors, optimized cleavable linkers and controlled drug-to-antibody ratios to strengthen bystander activity while managing systemic toxicity. Site-specific conjugation, biparatopic or bispecific antibodies, dual-payload architectures and immune-stimulating payloads represent the next layer of product innovation, although their manufacturing and regulatory requirements remain demanding. At the clinical level, combination regimens with immune checkpoint inhibitors and other targeted therapies are expanding the addressable population. Companion diagnostics, quantitative antigen testing and resistance monitoring are consequently becoming more important to patient selection, treatment sequencing and lifecycle management.
Market Dynamics
Drivers
Market expansion is being driven by the broadening of approved indications, movement into earlier treatment lines and continued validation of ADCs in major solid tumors. Successful products have demonstrated that an effective antibody, linker and payload combination can improve clinical outcomes in patients with limited alternatives, supporting physician adoption and premium oncology pricing. Pharmaceutical companies are increasing internal development, licensing and co-development investment because a validated ADC platform can generate multiple target-specific candidates. Growth is also reinforced by improved biomarker testing, expansion of oncology treatment infrastructure and increasing regulatory acceptance of ADCs across North America, Europe and Asia.
Restraints
ADC development and production involve substantially greater complexity than conventional monoclonal antibodies. Manufacturers must coordinate antibody production, high-potency payload synthesis, linker chemistry, conjugation, purification, aseptic filling and specialized analytical testing under tightly controlled conditions. Payload containment requirements, limited qualified capacity, long production lead times and low initial batch volumes increase unit costs. Commercial adoption may also be constrained by treatment-related toxicities, dose interruptions, regional reimbursement negotiations and the need for specialized infusion and adverse-event management. These factors can delay penetration even after regulatory approval.
Opportunities
The most attractive opportunities are emerging from new tumor targets, improved therapeutic windows and expansion beyond heavily pretreated patients. Targets such as B7-H3, HER3, CLDN18.2, c-MET and other tumor-associated antigens offer room for differentiated products, particularly where existing therapies provide limited durability. Further opportunities exist in earlier-stage disease, perioperative treatment, biomarker-defined pan-tumor indications and rational combinations with immunotherapy. Asia-Pacific offers additional potential through local clinical development, regional licensing, domestic manufacturing and broader reimbursement access. Platform suppliers and specialized contract manufacturers can also benefit as developers seek external capacity for payload production, conjugation and high-potency fill-finish operations.
Challenges
The principal challenge is maintaining a sufficiently wide therapeutic index while preserving strong antitumor activity. Antigen heterogeneity, variable internalization, payload resistance, linker instability and off-target toxicity can weaken clinical differentiation or limit dose intensity. Developers must also demonstrate superiority against rapidly changing standards of care, requiring larger and more expensive comparative trials. Intellectual-property overlap across antibodies, linkers, payloads and conjugation methods increases freedom-to-operate risk. Commercially, companies face indication crowding, pricing scrutiny and the possibility that competing ADCs, bispecific antibodies, radioligand therapies or other targeted modalities will reduce the value of late-entry products.
Industry Chain Analysis
The upstream ADC industry chain comprises monoclonal antibody cell lines and biologic drug substance, linker intermediates, highly potent payloads, conjugation reagents, chromatography resins, single-use processing systems and analytical materials. Payload and linker production require advanced organic synthesis, containment and impurity control, while antibody production relies on mature mammalian-cell bioprocessing. Midstream activities integrate antibody manufacture with conjugation, purification, formulation, sterile filling, quality testing and cold-chain release. Process consistency is critical because changes in drug-to-antibody ratio, free payload, aggregation or conjugation-site distribution can materially affect efficacy, safety and shelf life.
Value creation is concentrated in target validation, proprietary linker-payload chemistry, reproducible conjugation, clinical differentiation, regulatory execution and commercial access. Downstream products are distributed through oncology hospitals, specialist treatment centers, authorized pharmaceutical distributors and specialty channels, with payment influenced by indication, patient weight, treatment cycle, vial strength, reimbursement and negotiated discounts. Commercial ADCs can support high product-level gross margins, but development failures, pharmacovigilance, diagnostic support and post-approval trials consume substantial lifecycle investment. Supply reliability and capacity planning therefore remain important competitive factors alongside clinical performance.
Segment Insights
By payload mechanism, microtubule inhibitors retain a substantial installed commercial base through established products, while topoisomerase I inhibitors are gaining strategic importance because of their activity in solid tumors and potential bystander effect. DNA-damaging payloads remain important in selected hematologic indications but represent a narrower commercial segment. Cleavable linkers increasingly dominate newer product development because they facilitate intracellular or tumor-microenvironment payload release, whereas non-cleavable linkers retain relevance where plasma stability and controlled intracellular processing are prioritized.
Conventional stochastic conjugation remains widely used in marketed products because of established manufacturing experience and regulatory familiarity. However, site-specific and controlled conjugation technologies are attracting greater development investment because they can narrow drug-to-antibody ratio distribution and improve batch consistency. Solid tumors represent the largest application segment, led by breast, urothelial, lung, gynecologic and gastrointestinal cancers. Hematologic malignancies remain an important established segment, especially where validated lineage antigens support efficient internalization and clear patient selection.
Downstream Market Opportunities
The largest downstream opportunity lies in expanding ADCs from salvage therapy into earlier treatment lines and curative-intent settings. Breast cancer remains a major commercial foundation, while urothelial, lung, ovarian, cervical, gastric and other biomarker-defined solid tumors are creating additional demand. Treatment centers increasingly require integrated diagnostic testing, standardized toxicity-management pathways and dependable product availability rather than drug supply alone. Opportunities are also emerging from community oncology adoption, combination regimens and broader testing of low or heterogeneous antigen expression. Products that demonstrate clinically meaningful survival benefits, manageable adverse events and practical dosing schedules are better positioned to secure formulary access and sustained physician use.
Regional Insights
North America remains the largest Antibody-drug Conjugates market because the United States combines early regulatory launches, concentrated oncology expertise, broad biomarker testing and relatively high net drug prices. Commercial uptake can be rapid when an ADC receives a differentiated label or moves into an earlier treatment line, although payer controls and indication-specific reimbursement are becoming more influential. Europe represents a major but more price-controlled market, with country-level health technology assessment, reimbursement timing and treatment guidelines producing uneven launch curves.
Asia-Pacific is developing into the most dynamic regional opportunity. Japan combines established ADC innovation with advanced oncology infrastructure, while China is expanding domestic development, manufacturing capacity, regulatory approvals and commercial partnerships. Chinese products are also increasing licensing activity in international markets, strengthening the region’s role in global innovation rather than only local supply. Other emerging markets offer longer-term demand potential, but access remains constrained by oncology budgets, diagnostic availability, specialist capacity and cold-chain distribution.
Competitive Landscape Analysis
Competition is shifting from a small group of early ADC pioneers toward integrated global pharmaceutical portfolios and specialized platform companies. Daiichi Sankyo and AstraZeneca have established a strong position around the DXd platform, while Roche retains an important commercial franchise across solid tumors and hematologic malignancies. Pfizer’s acquisition of Seagen consolidated Padcev, Adcetris and Tivdak within a larger oncology organization, and AbbVie’s acquisition of ImmunoGen brought Elahere and related technology into its portfolio. Gilead, Astellas, GSK, Takeda and ADC Therapeutics compete through marketed products, partnerships or indication expansion. In China, RemeGen and Kelun-Biotech have entered commercial-stage competition, while Hengrui, Hansoh, CSPC, Mabwell, Duality Biologics, MediLink Therapeutics and other developers are advancing differentiated targets and linker-payload platforms. Future leadership will depend less on the number of pipeline candidates and more on clinical differentiation, manufacturing reproducibility, biomarker strategy, global regulatory execution, market access and the ability to manage combination development across multiple indications.
Report Scope
LPI (LP Information)' newest research report, the “Antibody-drug Conjugates Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates sales for 2026 through 2032. With Antibody-drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
HER2-Directed ADCs
TROP2-Directed ADCs
Hematologic-Lineage Antigen ADCs
Other Target Antigen ADCs
Segmentation by Payload Mechanism:
Topoisomerase I Inhibitor ADCs
Microtubule Inhibitor ADCs
DNA-Damaging ADCs
Other Payload ADCs
Segmentation by Drug-To-Antibody Ratio:
DAR Up To 4
DAR Above 4 And Below 8
DAR 8 And Above
Other
Segmentation by Application:
Breast and Gynecologic Malignancies
Lung and Other Thoracic Malignancies
Other Solid Tumors
Hematologic Malignancies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Daiichi Sankyo Company, Limited
Roche
Pfizer Inc.
Gilead Sciences, Inc.
Astellas Pharma Inc.
AbbVie Inc.
GSK plc
ADC Therapeutics SA
Takeda Pharmaceutical Company Limited
AstraZeneca plc
Genmab A/S
Johnson & Johnson
Merck & Co., Inc.
MacroGenics, Inc.
Sutro Biopharma, Inc.
Heidelberg Pharma AG
RemeGen Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Innovent Biologics, Inc.
CSPC Pharmaceutical Group Limited
Mabwell (Shanghai) Bioscience Co., Ltd.
Lepu Biopharma Co., Ltd.
Duality Biologics (Shanghai) Co., Ltd.
MediLink Therapeutics (Suzhou) Co., Ltd.
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Hangzhou DAC Biotechnology Co., Ltd.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
Sichuan Biokin Pharmaceutical Co., Ltd.
Bio-Thera Solutions, Ltd.

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antibody-drug Conjugates Market Size (2021-2032)
2.1.2 Antibody-drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Antibody-drug Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Antibody-drug Conjugates Segment by Type
2.2.1 HER2-Directed ADCs
2.2.2 TROP2-Directed ADCs
2.2.3 Hematologic-Lineage Antigen ADCs
2.2.4 Other Target Antigen ADCs
2.2.5 Antibody-drug Conjugates Market Size by Type
2.2.5.1 Antibody-drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Antibody-drug Conjugates Market Size Market Share by Type (2021-2026)
2.3 Antibody-drug Conjugates Segment by Payload Mechanism
2.3.1 Topoisomerase I Inhibitor ADCs
2.3.2 Microtubule Inhibitor ADCs
2.3.3 DNA-Damaging ADCs
2.3.4 Other Payload ADCs
2.3.5 Antibody-drug Conjugates Market Size by Payload Mechanism
2.3.5.1 Antibody-drug Conjugates Market Size CAGR by Payload Mechanism (2021 VS 2025 VS 2032)
2.3.5.2 Global Antibody-drug Conjugates Market Size Market Share by Payload Mechanism (2021-2026)
2.4 Antibody-drug Conjugates Segment by Drug-To-Antibody Ratio
2.4.1 DAR Up To 4
2.4.2 DAR Above 4 And Below 8
2.4.3 DAR 8 And Above
2.4.4 Other
2.4.5 Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio
2.4.5.1 Antibody-drug Conjugates Market Size CAGR by Drug-To-Antibody Ratio (2021 VS 2025 VS 2032)
2.4.5.2 Global Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio (2021-2026)
2.5 Antibody-drug Conjugates Segment by Application
2.5.1 Breast and Gynecologic Malignancies
2.5.2 Lung and Other Thoracic Malignancies
2.5.3 Other Solid Tumors
2.5.4 Hematologic Malignancies
2.5.5 Antibody-drug Conjugates Market Size by Application
2.5.5.1 Antibody-drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global Antibody-drug Conjugates Market Size Market Share by Application (2021-2026)

3 Antibody-drug Conjugates Market Size by Player
3.1 Antibody-drug Conjugates Market Size Market Share by Player
3.1.1 Global Antibody-drug Conjugates Revenue by Player (2021-2026)
3.1.2 Global Antibody-drug Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Antibody-drug Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Antibody-drug Conjugates by Region
4.1 Antibody-drug Conjugates Market Size by Region (2021-2026)
4.2 Global Antibody-drug Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antibody-drug Conjugates Market Size Growth (2021-2026)
4.4 APAC Antibody-drug Conjugates Market Size Growth (2021-2026)
4.5 Europe Antibody-drug Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Antibody-drug Conjugates Market Size Growth (2021-2026)

5 Americas
5.1 Americas Antibody-drug Conjugates Market Size by Country (2021-2026)
5.2 Americas Antibody-drug Conjugates Market Size by Type (2021-2026)
5.3 Americas Antibody-drug Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Antibody-drug Conjugates Market Size by Region (2021-2026)
6.2 APAC Antibody-drug Conjugates Market Size by Type (2021-2026)
6.3 APAC Antibody-drug Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Antibody-drug Conjugates Market Size by Country (2021-2026)
7.2 Europe Antibody-drug Conjugates Market Size by Type (2021-2026)
7.3 Europe Antibody-drug Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Antibody-drug Conjugates by Region (2021-2026)
8.2 Middle East & Africa Antibody-drug Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Antibody-drug Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 Global Antibody-drug Conjugates Market Forecast
10.1 Global Antibody-drug Conjugates Forecast by Region (2027-2032)
10.1.1 Global Antibody-drug Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Antibody-drug Conjugates Forecast
10.1.3 APAC Antibody-drug Conjugates Forecast
10.1.4 Europe Antibody-drug Conjugates Forecast
10.1.5 Middle East & Africa Antibody-drug Conjugates Forecast
10.2 Americas Antibody-drug Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Antibody-drug Conjugates Forecast
10.2.2 Canada Market Antibody-drug Conjugates Forecast
10.2.3 Mexico Market Antibody-drug Conjugates Forecast
10.2.4 Brazil Market Antibody-drug Conjugates Forecast
10.3 APAC Antibody-drug Conjugates Forecast by Region (2027-2032)
10.3.1 China Antibody-drug Conjugates Market Forecast
10.3.2 Japan Market Antibody-drug Conjugates Forecast
10.3.3 Korea Market Antibody-drug Conjugates Forecast
10.3.4 Southeast Asia Market Antibody-drug Conjugates Forecast
10.3.5 India Market Antibody-drug Conjugates Forecast
10.3.6 Australia Market Antibody-drug Conjugates Forecast
10.4 Europe Antibody-drug Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Antibody-drug Conjugates Forecast
10.4.2 France Market Antibody-drug Conjugates Forecast
10.4.3 UK Market Antibody-drug Conjugates Forecast
10.4.4 Italy Market Antibody-drug Conjugates Forecast
10.4.5 Russia Market Antibody-drug Conjugates Forecast
10.5 Middle East & Africa Antibody-drug Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Antibody-drug Conjugates Forecast
10.5.2 South Africa Market Antibody-drug Conjugates Forecast
10.5.3 Israel Market Antibody-drug Conjugates Forecast
10.5.4 Turkey Market Antibody-drug Conjugates Forecast
10.6 Global Antibody-drug Conjugates Forecast by Type (2027-2032)
10.7 Global Antibody-drug Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Antibody-drug Conjugates Forecast

11 Key Players Analysis
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Company Information
11.1.2 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product Offered
11.1.3 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Daiichi Sankyo Company, Limited Main Business Overview
11.1.5 Daiichi Sankyo Company, Limited Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Antibody-drug Conjugates Product Offered
11.2.3 Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Information
11.3.2 Pfizer Inc. Antibody-drug Conjugates Product Offered
11.3.3 Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Pfizer Inc. Main Business Overview
11.3.5 Pfizer Inc. Latest Developments
11.4 Gilead Sciences, Inc.
11.4.1 Gilead Sciences, Inc. Company Information
11.4.2 Gilead Sciences, Inc. Antibody-drug Conjugates Product Offered
11.4.3 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Gilead Sciences, Inc. Main Business Overview
11.4.5 Gilead Sciences, Inc. Latest Developments
11.5 Astellas Pharma Inc.
11.5.1 Astellas Pharma Inc. Company Information
11.5.2 Astellas Pharma Inc. Antibody-drug Conjugates Product Offered
11.5.3 Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Astellas Pharma Inc. Main Business Overview
11.5.5 Astellas Pharma Inc. Latest Developments
11.6 AbbVie Inc.
11.6.1 AbbVie Inc. Company Information
11.6.2 AbbVie Inc. Antibody-drug Conjugates Product Offered
11.6.3 AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 AbbVie Inc. Main Business Overview
11.6.5 AbbVie Inc. Latest Developments
11.7 GSK plc
11.7.1 GSK plc Company Information
11.7.2 GSK plc Antibody-drug Conjugates Product Offered
11.7.3 GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 GSK plc Main Business Overview
11.7.5 GSK plc Latest Developments
11.8 ADC Therapeutics SA
11.8.1 ADC Therapeutics SA Company Information
11.8.2 ADC Therapeutics SA Antibody-drug Conjugates Product Offered
11.8.3 ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 ADC Therapeutics SA Main Business Overview
11.8.5 ADC Therapeutics SA Latest Developments
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Information
11.9.2 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product Offered
11.9.3 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.9.5 Takeda Pharmaceutical Company Limited Latest Developments
11.10 AstraZeneca plc
11.10.1 AstraZeneca plc Company Information
11.10.2 AstraZeneca plc Antibody-drug Conjugates Product Offered
11.10.3 AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 AstraZeneca plc Main Business Overview
11.10.5 AstraZeneca plc Latest Developments
11.11 Genmab A/S
11.11.1 Genmab A/S Company Information
11.11.2 Genmab A/S Antibody-drug Conjugates Product Offered
11.11.3 Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Genmab A/S Main Business Overview
11.11.5 Genmab A/S Latest Developments
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Company Information
11.12.2 Johnson & Johnson Antibody-drug Conjugates Product Offered
11.12.3 Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Johnson & Johnson Main Business Overview
11.12.5 Johnson & Johnson Latest Developments
11.13 Merck & Co., Inc.
11.13.1 Merck & Co., Inc. Company Information
11.13.2 Merck & Co., Inc. Antibody-drug Conjugates Product Offered
11.13.3 Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Merck & Co., Inc. Main Business Overview
11.13.5 Merck & Co., Inc. Latest Developments
11.14 MacroGenics, Inc.
11.14.1 MacroGenics, Inc. Company Information
11.14.2 MacroGenics, Inc. Antibody-drug Conjugates Product Offered
11.14.3 MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 MacroGenics, Inc. Main Business Overview
11.14.5 MacroGenics, Inc. Latest Developments
11.15 Sutro Biopharma, Inc.
11.15.1 Sutro Biopharma, Inc. Company Information
11.15.2 Sutro Biopharma, Inc. Antibody-drug Conjugates Product Offered
11.15.3 Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Sutro Biopharma, Inc. Main Business Overview
11.15.5 Sutro Biopharma, Inc. Latest Developments
11.16 Heidelberg Pharma AG
11.16.1 Heidelberg Pharma AG Company Information
11.16.2 Heidelberg Pharma AG Antibody-drug Conjugates Product Offered
11.16.3 Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Heidelberg Pharma AG Main Business Overview
11.16.5 Heidelberg Pharma AG Latest Developments
11.17 RemeGen Co., Ltd.
11.17.1 RemeGen Co., Ltd. Company Information
11.17.2 RemeGen Co., Ltd. Antibody-drug Conjugates Product Offered
11.17.3 RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 RemeGen Co., Ltd. Main Business Overview
11.17.5 RemeGen Co., Ltd. Latest Developments
11.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
11.18.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Company Information
11.18.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product Offered
11.18.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Main Business Overview
11.18.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Latest Developments
11.19 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.19.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Information
11.19.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product Offered
11.19.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Main Business Overview
11.19.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Latest Developments
11.20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
11.20.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information
11.20.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product Offered
11.20.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Main Business Overview
11.20.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Latest Developments
11.21 Innovent Biologics, Inc.
11.21.1 Innovent Biologics, Inc. Company Information
11.21.2 Innovent Biologics, Inc. Antibody-drug Conjugates Product Offered
11.21.3 Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Innovent Biologics, Inc. Main Business Overview
11.21.5 Innovent Biologics, Inc. Latest Developments
11.22 CSPC Pharmaceutical Group Limited
11.22.1 CSPC Pharmaceutical Group Limited Company Information
11.22.2 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product Offered
11.22.3 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 CSPC Pharmaceutical Group Limited Main Business Overview
11.22.5 CSPC Pharmaceutical Group Limited Latest Developments
11.23 Mabwell (Shanghai) Bioscience Co., Ltd.
11.23.1 Mabwell (Shanghai) Bioscience Co., Ltd. Company Information
11.23.2 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product Offered
11.23.3 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Mabwell (Shanghai) Bioscience Co., Ltd. Main Business Overview
11.23.5 Mabwell (Shanghai) Bioscience Co., Ltd. Latest Developments
11.24 Lepu Biopharma Co., Ltd.
11.24.1 Lepu Biopharma Co., Ltd. Company Information
11.24.2 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product Offered
11.24.3 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Lepu Biopharma Co., Ltd. Main Business Overview
11.24.5 Lepu Biopharma Co., Ltd. Latest Developments
11.25 Duality Biologics (Shanghai) Co., Ltd.
11.25.1 Duality Biologics (Shanghai) Co., Ltd. Company Information
11.25.2 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product Offered
11.25.3 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Duality Biologics (Shanghai) Co., Ltd. Main Business Overview
11.25.5 Duality Biologics (Shanghai) Co., Ltd. Latest Developments
11.26 MediLink Therapeutics (Suzhou) Co., Ltd.
11.26.1 MediLink Therapeutics (Suzhou) Co., Ltd. Company Information
11.26.2 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product Offered
11.26.3 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 MediLink Therapeutics (Suzhou) Co., Ltd. Main Business Overview
11.26.5 MediLink Therapeutics (Suzhou) Co., Ltd. Latest Developments
11.27 GeneQuantum Healthcare (Suzhou) Co., Ltd.
11.27.1 GeneQuantum Healthcare (Suzhou) Co., Ltd. Company Information
11.27.2 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product Offered
11.27.3 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.27.4 GeneQuantum Healthcare (Suzhou) Co., Ltd. Main Business Overview
11.27.5 GeneQuantum Healthcare (Suzhou) Co., Ltd. Latest Developments
11.28 Hangzhou DAC Biotechnology Co., Ltd.
11.28.1 Hangzhou DAC Biotechnology Co., Ltd. Company Information
11.28.2 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product Offered
11.28.3 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.28.4 Hangzhou DAC Biotechnology Co., Ltd. Main Business Overview
11.28.5 Hangzhou DAC Biotechnology Co., Ltd. Latest Developments
11.29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
11.29.1 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Company Information
11.29.2 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product Offered
11.29.3 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.29.4 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Main Business Overview
11.29.5 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Latest Developments
11.30 Sichuan Biokin Pharmaceutical Co., Ltd.
11.30.1 Sichuan Biokin Pharmaceutical Co., Ltd. Company Information
11.30.2 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product Offered
11.30.3 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.30.4 Sichuan Biokin Pharmaceutical Co., Ltd. Main Business Overview
11.30.5 Sichuan Biokin Pharmaceutical Co., Ltd. Latest Developments
11.31 Bio-Thera Solutions, Ltd.
11.31.1 Bio-Thera Solutions, Ltd. Company Information
11.31.2 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product Offered
11.31.3 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.31.4 Bio-Thera Solutions, Ltd. Main Business Overview
11.31.5 Bio-Thera Solutions, Ltd. Latest Developments

12 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Antibody-drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Antibody-drug Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of HER2-Directed ADCs
Table 4. Major Players of TROP2-Directed ADCs
Table 5. Major Players of Hematologic-Lineage Antigen ADCs
Table 6. Major Players of Other Target Antigen ADCs
Table 7. Antibody-drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Antibody-drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Antibody-drug Conjugates Market Size Market Share by Type (2021-2026)
Table 10. Major Players of Topoisomerase I Inhibitor ADCs
Table 11. Major Players of Microtubule Inhibitor ADCs
Table 12. Major Players of DNA-Damaging ADCs
Table 13. Major Players of Other Payload ADCs
Table 14. Antibody-drug Conjugates Market Size CAGR by Payload Mechanism (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Antibody-drug Conjugates Market Size by Payload Mechanism (2021-2026) & ($ millions)
Table 16. Global Antibody-drug Conjugates Market Size Market Share by Payload Mechanism (2021-2026)
Table 17. Major Players of DAR Up To 4
Table 18. Major Players of DAR Above 4 And Below 8
Table 19. Major Players of DAR 8 And Above
Table 20. Major Players of Other
Table 21. Antibody-drug Conjugates Market Size CAGR by Drug-To-Antibody Ratio (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2021-2026) & ($ millions)
Table 23. Global Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio (2021-2026)
Table 24. Antibody-drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Antibody-drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 26. Global Antibody-drug Conjugates Market Size Market Share by Application (2021-2026)
Table 27. Global Antibody-drug Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 28. Global Antibody-drug Conjugates Revenue Market Share by Player (2021-2026)
Table 29. Antibody-drug Conjugates Key Players Head office and Products Offered
Table 30. Antibody-drug Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global Antibody-drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 34. Global Antibody-drug Conjugates Market Size Market Share by Region (2021-2026)
Table 35. Global Antibody-drug Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Antibody-drug Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Antibody-drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 38. Americas Antibody-drug Conjugates Market Size Market Share by Country (2021-2026)
Table 39. Americas Antibody-drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 40. Americas Antibody-drug Conjugates Market Size Market Share by Type (2021-2026)
Table 41. Americas Antibody-drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 42. Americas Antibody-drug Conjugates Market Size Market Share by Application (2021-2026)
Table 43. APAC Antibody-drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 44. APAC Antibody-drug Conjugates Market Size Market Share by Region (2021-2026)
Table 45. APAC Antibody-drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 46. APAC Antibody-drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 47. Europe Antibody-drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 48. Europe Antibody-drug Conjugates Market Size Market Share by Country (2021-2026)
Table 49. Europe Antibody-drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 50. Europe Antibody-drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 51. Middle East & Africa Antibody-drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 52. Middle East & Africa Antibody-drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 53. Middle East & Africa Antibody-drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 54. Key Market Drivers & Growth Opportunities of Antibody-drug Conjugates
Table 55. Key Market Challenges & Risks of Antibody-drug Conjugates
Table 56. Key Industry Trends of Antibody-drug Conjugates
Table 57. Global Antibody-drug Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 58. Global Antibody-drug Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 59. Global Antibody-drug Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 60. Global Antibody-drug Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 61. Daiichi Sankyo Company, Limited Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 62. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product Offered
Table 63. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Daiichi Sankyo Company, Limited Main Business
Table 65. Daiichi Sankyo Company, Limited Latest Developments
Table 66. Roche Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 67. Roche Antibody-drug Conjugates Product Offered
Table 68. Roche Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Roche Main Business
Table 70. Roche Latest Developments
Table 71. Pfizer Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 72. Pfizer Inc. Antibody-drug Conjugates Product Offered
Table 73. Pfizer Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Pfizer Inc. Main Business
Table 75. Pfizer Inc. Latest Developments
Table 76. Gilead Sciences, Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 77. Gilead Sciences, Inc. Antibody-drug Conjugates Product Offered
Table 78. Gilead Sciences, Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Gilead Sciences, Inc. Main Business
Table 80. Gilead Sciences, Inc. Latest Developments
Table 81. Astellas Pharma Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 82. Astellas Pharma Inc. Antibody-drug Conjugates Product Offered
Table 83. Astellas Pharma Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Astellas Pharma Inc. Main Business
Table 85. Astellas Pharma Inc. Latest Developments
Table 86. AbbVie Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 87. AbbVie Inc. Antibody-drug Conjugates Product Offered
Table 88. AbbVie Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. AbbVie Inc. Main Business
Table 90. AbbVie Inc. Latest Developments
Table 91. GSK plc Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 92. GSK plc Antibody-drug Conjugates Product Offered
Table 93. GSK plc Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. GSK plc Main Business
Table 95. GSK plc Latest Developments
Table 96. ADC Therapeutics SA Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 97. ADC Therapeutics SA Antibody-drug Conjugates Product Offered
Table 98. ADC Therapeutics SA Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. ADC Therapeutics SA Main Business
Table 100. ADC Therapeutics SA Latest Developments
Table 101. Takeda Pharmaceutical Company Limited Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 102. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product Offered
Table 103. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Takeda Pharmaceutical Company Limited Main Business
Table 105. Takeda Pharmaceutical Company Limited Latest Developments
Table 106. AstraZeneca plc Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 107. AstraZeneca plc Antibody-drug Conjugates Product Offered
Table 108. AstraZeneca plc Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. AstraZeneca plc Main Business
Table 110. AstraZeneca plc Latest Developments
Table 111. Genmab A/S Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 112. Genmab A/S Antibody-drug Conjugates Product Offered
Table 113. Genmab A/S Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Genmab A/S Main Business
Table 115. Genmab A/S Latest Developments
Table 116. Johnson & Johnson Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 117. Johnson & Johnson Antibody-drug Conjugates Product Offered
Table 118. Johnson & Johnson Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Johnson & Johnson Main Business
Table 120. Johnson & Johnson Latest Developments
Table 121. Merck & Co., Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 122. Merck & Co., Inc. Antibody-drug Conjugates Product Offered
Table 123. Merck & Co., Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Merck & Co., Inc. Main Business
Table 125. Merck & Co., Inc. Latest Developments
Table 126. MacroGenics, Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 127. MacroGenics, Inc. Antibody-drug Conjugates Product Offered
Table 128. MacroGenics, Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. MacroGenics, Inc. Main Business
Table 130. MacroGenics, Inc. Latest Developments
Table 131. Sutro Biopharma, Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 132. Sutro Biopharma, Inc. Antibody-drug Conjugates Product Offered
Table 133. Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Sutro Biopharma, Inc. Main Business
Table 135. Sutro Biopharma, Inc. Latest Developments
Table 136. Heidelberg Pharma AG Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 137. Heidelberg Pharma AG Antibody-drug Conjugates Product Offered
Table 138. Heidelberg Pharma AG Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Heidelberg Pharma AG Main Business
Table 140. Heidelberg Pharma AG Latest Developments
Table 141. RemeGen Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 142. RemeGen Co., Ltd. Antibody-drug Conjugates Product Offered
Table 143. RemeGen Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. RemeGen Co., Ltd. Main Business
Table 145. RemeGen Co., Ltd. Latest Developments
Table 146. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 147. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product Offered
Table 148. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 149. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Main Business
Table 150. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Latest Developments
Table 151. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 152. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product Offered
Table 153. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 154. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Main Business
Table 155. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Latest Developments
Table 156. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 157. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product Offered
Table 158. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 159. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Main Business
Table 160. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Latest Developments
Table 161. Innovent Biologics, Inc. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 162. Innovent Biologics, Inc. Antibody-drug Conjugates Product Offered
Table 163. Innovent Biologics, Inc. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 164. Innovent Biologics, Inc. Main Business
Table 165. Innovent Biologics, Inc. Latest Developments
Table 166. CSPC Pharmaceutical Group Limited Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 167. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product Offered
Table 168. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 169. CSPC Pharmaceutical Group Limited Main Business
Table 170. CSPC Pharmaceutical Group Limited Latest Developments
Table 171. Mabwell (Shanghai) Bioscience Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 172. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product Offered
Table 173. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 174. Mabwell (Shanghai) Bioscience Co., Ltd. Main Business
Table 175. Mabwell (Shanghai) Bioscience Co., Ltd. Latest Developments
Table 176. Lepu Biopharma Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 177. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product Offered
Table 178. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 179. Lepu Biopharma Co., Ltd. Main Business
Table 180. Lepu Biopharma Co., Ltd. Latest Developments
Table 181. Duality Biologics (Shanghai) Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 182. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product Offered
Table 183. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 184. Duality Biologics (Shanghai) Co., Ltd. Main Business
Table 185. Duality Biologics (Shanghai) Co., Ltd. Latest Developments
Table 186. MediLink Therapeutics (Suzhou) Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 187. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product Offered
Table 188. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 189. MediLink Therapeutics (Suzhou) Co., Ltd. Main Business
Table 190. MediLink Therapeutics (Suzhou) Co., Ltd. Latest Developments
Table 191. GeneQuantum Healthcare (Suzhou) Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 192. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product Offered
Table 193. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 194. GeneQuantum Healthcare (Suzhou) Co., Ltd. Main Business
Table 195. GeneQuantum Healthcare (Suzhou) Co., Ltd. Latest Developments
Table 196. Hangzhou DAC Biotechnology Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 197. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product Offered
Table 198. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 199. Hangzhou DAC Biotechnology Co., Ltd. Main Business
Table 200. Hangzhou DAC Biotechnology Co., Ltd. Latest Developments
Table 201. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 202. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product Offered
Table 203. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 204. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Main Business
Table 205. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Latest Developments
Table 206. Sichuan Biokin Pharmaceutical Co., Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 207. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product Offered
Table 208. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 209. Sichuan Biokin Pharmaceutical Co., Ltd. Main Business
Table 210. Sichuan Biokin Pharmaceutical Co., Ltd. Latest Developments
Table 211. Bio-Thera Solutions, Ltd. Details, Company Type, Antibody-drug Conjugates Area Served and Its Competitors
Table 212. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product Offered
Table 213. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 214. Bio-Thera Solutions, Ltd. Main Business
Table 215. Bio-Thera Solutions, Ltd. Latest Developments

List of Figures
Figure 1. Antibody-drug Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antibody-drug Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Antibody-drug Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Antibody-drug Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Antibody-drug Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Antibody-drug Conjugates Market Size Market Share by Type in 2025
Figure 10. Global Antibody-drug Conjugates Market Size Market Share by Payload Mechanism in 2025
Figure 11. Global Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio in 2025
Figure 12. Antibody-drug Conjugates in Breast and Gynecologic Malignancies
Figure 13. Global Antibody-drug Conjugates Market: Breast and Gynecologic Malignancies (2021-2026) & ($ millions)
Figure 14. Antibody-drug Conjugates in Lung and Other Thoracic Malignancies
Figure 15. Global Antibody-drug Conjugates Market: Lung and Other Thoracic Malignancies (2021-2026) & ($ millions)
Figure 16. Antibody-drug Conjugates in Other Solid Tumors
Figure 17. Global Antibody-drug Conjugates Market: Other Solid Tumors (2021-2026) & ($ millions)
Figure 18. Antibody-drug Conjugates in Hematologic Malignancies
Figure 19. Global Antibody-drug Conjugates Market: Hematologic Malignancies (2021-2026) & ($ millions)
Figure 20. Global Antibody-drug Conjugates Market Size Market Share by Application in 2025
Figure 21. Global Antibody-drug Conjugates Revenue Market Share by Player in 2025
Figure 22. Global Antibody-drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 23. Americas Antibody-drug Conjugates Market Size 2021-2026 ($ millions)
Figure 24. APAC Antibody-drug Conjugates Market Size 2021-2026 ($ millions)
Figure 25. Europe Antibody-drug Conjugates Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Antibody-drug Conjugates Market Size 2021-2026 ($ millions)
Figure 27. Americas Antibody-drug Conjugates Value Market Share by Country in 2025
Figure 28. United States Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Antibody-drug Conjugates Market Size Market Share by Region in 2025
Figure 33. APAC Antibody-drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 34. APAC Antibody-drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 35. China Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. India Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Antibody-drug Conjugates Market Size Market Share by Country in 2025
Figure 42. Europe Antibody-drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 43. Europe Antibody-drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 44. Germany Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 45. France Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Antibody-drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Antibody-drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Antibody-drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Antibody-drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 58. APAC Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 59. Europe Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 61. United States Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Canada Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 63. Mexico Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Brazil Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 65. China Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 66. Japan Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 67. Korea Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 69. India Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 70. Australia Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 71. Germany Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 72. France Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 73. UK Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Italy Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 75. Russia Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 76. Egypt Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 77. South Africa Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 78. Israel Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 79. Turkey Antibody-drug Conjugates Market Size 2027-2032 ($ millions)
Figure 80. Global Antibody-drug Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Antibody-drug Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Antibody-drug Conjugates Market Size 2027-2032 ($ millions)